問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間:2023-09-19

蔡瑞鴻Tsai, Jui-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

篩選

List

229Cases

2025-07-15 - 2030-12-31

Phase II

Active
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
  • Condition/Disease

    Malignant Neoplasm

  • Test Drug

    Tablets Tablets Injections Tablets Injections Tablets

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2027-08-22

Phase II

Not yet recruiting
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
  • Condition/Disease

    Nausea

  • Test Drug

    subcutaneous injection

Participate Sites
5Sites

Recruiting5Sites

2020-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2025-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2017-07-15 - 2022-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2023-03-01 - 2027-12-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2023-04-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2025-02-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2020-12-01 - 2025-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites